OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
IPHYF
Innate Pharma
Ordinary Shares
2.00
0.00
0.00%
1.34 / 2.32 (1 x 1)
Real-Time Best Bid & Ask: 05:00pm 11/14/2025
Delayed (15 Min) Trade Data: 12:00am 10/02/2025
Innate Pharma
117, Avenue de Luminy - BP 30191
Marseille 13 009
France
www.innate-pharma.com
+ 33 (0) 4 30 30 30
Business Description
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells.
The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms.
Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.
Based in Marseille, France, Innate ...
More
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
CIK
0001598599
Fiscal Year End
12/31
Company Officers & Contacts
Not available
Board of Directors
Not available
Other Company Insiders
Not available
Service Providers
Accounting/Auditing Firm
Deloitte et AssociesTour Majunga
6 Place de la Pyramide
Puteaux 92908
France
Profile Data
SIC - Industry Classification
2836 - Biological products, except diagnostic
Incorporation Information
FR, 1999
Employees
122 as of 03/31/2016
Shell
No
Products and Services
Not available
Company Facilities
Not available
The Pink Limited Market is for broker-dealers to publicly quote securities with limited to no issuer involvement. Pink Limited companies do not certify their compliance with established reporting standards, have limited availability of disclosure or financial information and may not support their U.S. market. These securities are identified with a yield sign to warn investors to proceed with caution.
Pink Limited Market
Securities
Other Innate Pharma Securities
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Loading...
Symbol
OTCM
Last
54.30
Change
-0.19 (-0.35%)
Bid
54.31
Ask
54.50
Volume
941
Time
00:00
© 2025 OTC Markets Group Inc.
Terms of ServiceLinking TermsTrademarksPrivacy StatementCode of ConductRisk WarningSupported Browsers